Small-molecule agonists for the glucagon-like peptide 1 receptor
- 16 January 2007
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 104 (3), 937-942
- https://doi.org/10.1073/pnas.0605701104
Abstract
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes. As a peptide hormone, GLP-1 has to be administered by injection. Only a few small-molecule agonists to peptide hormone receptors have been described and none in the B family of the G protein coupled receptors to which the GLP-1 receptor belongs. We have discovered a series of small molecules known as ago-allosteric modulators selective for the human GLP-1 receptor. These compounds act as both allosteric activators of the receptor and independent agonists. Potency of GLP-1 was not changed by the allosteric agonists, but affinity of GLP-1 for the receptor was increased. The most potent compound identified stimulates glucose-dependent insulin release from normal mouse islets but, importantly, not from GLP-1 receptor knockout mice. Also, the compound stimulates insulin release from perfused rat pancreas in a manner additive with GLP-1 itself. These compounds may lead to the identification or design of orally active GLP-1 agonists.Keywords
This publication has 50 references indexed in Scilit:
- Principles: Receptor theory in pharmacologyTrends in Pharmacological Sciences, 2004
- Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivityBritish Journal of Pharmacology, 2003
- Metal Ion-mediated Agonism and Agonist Enhancement in Melanocortin MC1 and MC4 ReceptorsPublished by Elsevier BV ,2002
- GPCR Drug Discovery Through the Exploitation of Allosteric Drug Binding SitesReceptors and Channels, 2002
- Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic ReceptorPublished by Elsevier BV ,2001
- Characterization of a novel nonpeptide vasopressin V2‐agonist, OPC‐51803, in cells transfected human vasopressin receptor subtypesBritish Journal of Pharmacology, 2000
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Non-peptide Angiotensin Agonist: FUNCTIONAL AND MOLECULAR INTERACTION WITH THE AT1 RECEPTORPublished by Elsevier BV ,1995
- A Nonpeptidyl Growth Hormone SecretagogueScience, 1993
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992